Experience of successful use of a combination of methylsulfonylmethane, vitamin C and native collagen-2 in a patient with osteoarthritis of the knee joints on the background of obesity: a clinical case

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Background. The article describes a case of successful treatment of a patient with Kellgren stage 1–2 knee osteoarthritis with obesity using a combination of methylsulfonylmethane, vitamin C and native collagen-2 as a non-drug treatment method.

Description of the clinical case. In patient M., the dynamics of pain articular syndrome with obesity was analyzed during treatment with a combination of methylsulfonylmethane, vitamin C and native collagen-2 for 60 days. Already on the 20th day of treatment, and fter 60 days, the pain in the joint, stiffness, and crepitus significantly decreased. There was a significant positive dynamics of laboratory, biochemical and ultrasound examination results.

Discussion. This clinical case clearly showed the effectiveness and safety of a combination of methylsulfonylmethane, vitamin C and native collagen-2, the rapid positive dynamics of the symptoms of the disease, results of additional laboratory and instrumental methods of examination.

Conclusion. The combination of methylsulfonylmethane, vitamin C and native collagen-2 can be recommended for use in patients with osteoarthritis in the early stages of the disease.

作者简介

L. Vasilyeva

Voronezh State Medical University n.a. N.N. Burdenko

Email: suslova_ekaterina2502@mail.ru
ORCID iD: 0000-0002-9900-556X
俄罗斯联邦, Voronezh

E. Gosteva

Voronezh State Medical University n.a. N.N. Burdenko

Email: suslova_ekaterina2502@mail.ru
ORCID iD: 0000-0002-8771-2558
俄罗斯联邦, Voronezh

E. Evstratova

Voronezh State Medical University n.a. N.N. Burdenko

Email: suslova_ekaterina2502@mail.ru
ORCID iD: 0000-0001-9343-6222
俄罗斯联邦, Voronezh

Ekaterina Suslova

Voronezh State Medical University n.a. N.N. Burdenko

编辑信件的主要联系方式.
Email: suslova_ekaterina2502@mail.ru
ORCID iD: 0000-0002-5407-0384
SPIN 代码: 5407-0384

Cand. Sci. (Med.), Associate Professor, Department of Propaedeutics of Internal Diseases

俄罗斯联邦, Voronezh

参考

  1. Васильева Л.В., Евстратова Е.Ф., Суслова Е.Ю. Применение инъекционной формы хондроитина сульфата в комбинации с дозированной физической нагрузкой для лечения пациентов с остеоартритом cуставов кистей. Современная ревматология. 2020;14(3):79–83. [Vasilyeva L.V., Evstratova E.F., Suslova E.Yu. The use of an injectable form of chondroitin sulfate in combination with dosed physical activity for the treatment of patients with osteoarthritis of the joints of the hands. Sovremennaya Revmatologiya. 2020;14(3):79–83. (In Russ.)]. doi: 10.14412/1996-7012-2020-3-79-83.
  2. Торшин И.Ю., Лила А.М., Наумов А.В. и др. Мета-анализ клинических исследований эффективности лечения остеоартрита препаратом Хондрогард Современная фармакоэкономика и фармакоэпидемиология, 2020.13;(4):18–26. [Torshin I.YU., Lila A.M., Naumov A.V. et al. Meta-analysis of clinical studies of the effectiveness of the treatment of osteoarthritis with Chondrogard. Sovremennaya farmakoekonomika i farmakoepidemiologiya 2020.13;(4):18–26. (In Russ.)] doi: 10.17749/2070-4909/farmakoekonomika.2020.066.
  3. Аникин С.Г., Кашеварова Н.Г., Короткова Т.А. и др. Оценка эффективности, переносимости и безопасности внутрисуставного введения гиалуроновой кислоты у больных с остеоартритом коленных суставов. Современная ревматология. 2017;11(3):58–63. [Anikin S.G., Kashevarova N.G., Korotkova T.A. et al. Evaluation of the efficacy, tolerability, and safety of intra-articular hyaluronic acid in patients with knee osteoarthritis. Sovremennaya Revmatologiya 2017;11(3):58–63. (In Russ.)]. doi: 10.14412/1996-7012-2017-3-58-63.
  4. «Клинические рекомендации – «Гонартроз» (утв. Минздравом России) – 2021. [«Clinical recommendations – «Gonarthrosis» (approved by the Ministry of Health of Russia) – 2021. (In Russ.)].
  5. Алексеева Л.И., Таскина Е.А., Кашеварова Н.Г. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение. Современная ревматология. 2019;13(2):9–21. [Alekseeva L.I., Taskina E.A., Kashevarova N.G. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya Revmatologiya. 2019;13(2):9–21. (In Russ.)]. doi: 10.14412/1996-7012-2019-2-9-21.
  6. Шавловская О.А., Громова О.А., Торшин И.Ю. Точки приложения неденатурированного коллагена II типа в терапии скелетно-мышечных болевых синдромов. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(11):40–45. [Shavlovskaya O.A, Gromova O.A, Torshin I.Yu. Points of undenatured type II collagen application in musculoskeletal pain syndromes treatment. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2022;122(11):40 45. (In Russ.)]. doi: 10.17116/jnevro202212211140.
  7. Lugo J.P,. Saiyed Z.M, Lau F.C., et al. Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Soc Sports Nutr 2013;10(1):48. doi: 10.1186/1550- 2783-10-48.
  8. Духанин А.С. Симптом-модифицирующие препараты замедленного действия в лечении остеоартрита: от молекулы к клиническому эффекту (взгляд фармаколога). Современная ревматология. 2018;12(2):79–87. [Dukhanin A.S. Symptom-modifying slow-acting drugs in the treatment of osteoarthritis: from molecule to clinical effect (a pharmacologist’s view). Sovremennaya Revmatologiya. 2018;12(2):79–87. (In Russ.)]. doi: 10.14412/1996-7012-2018-2-79-87.
##common.cookie##